

# Cihan YurdaydÄ±n

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4990492/publications.pdf>

Version: 2024-02-01

128  
papers

7,474  
citations

57758

44  
h-index

54911

84  
g-index

175  
all docs

175  
docs citations

175  
times ranked

4883  
citing authors

#	ARTICLE	IF	CITATIONS
1	HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta. <i>Hepatology Communications</i> , 2022, 6, 480-495.	4.3	15
2	A phase 2 doseâ€ndefining study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis. <i>Hepatology</i> , 2022, 75, 1551-1565.	7.3	41
3	Letter to the Editor: Interferon Is Not an Optimal Treatment for Chronic Hepatitis Delta but Needs â€œFair Treatmentâ€by Us. <i>Hepatology</i> , 2021, 74, 1127-1127.	7.3	0
4	The case for simplifying and using absolute targets for viral hepatitis elimination goals. <i>Journal of Viral Hepatitis</i> , 2021, 28, 12-19.	2.0	28
5	A transient early HBVâ€DNA increase during PEGâ€FNâ€ therapy of hepatitis D indicates loss of infected cells and is associated with HDVâ€RNA and HBsAg reduction. <i>Journal of Viral Hepatitis</i> , 2021, 28, 410-419.	2.0	5
6	Residual low HDV viraemia is associated HDV RNA relapse after PEGâ€FNâ€based antiviral treatment of hepatitis delta: Results from the HIDITâ€ study. <i>Liver International</i> , 2021, 41, 295-299.	3.9	18
7	Developing New Therapies for Delta Hepatitis: The Race Is On. <i>Hepatology Communications</i> , 2021, 5, 556-558.	4.3	1
8	Determination of Turkish norms of psychometric tests for diagnosing minimal hepatic encephalopathy and proposal of a high sensitive screening test battery. <i>Hepatology International</i> , 2021, 15, 1442-1455.	4.2	1
9	Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B. <i>JHEP Reports</i> , 2021, 3, 100290.	4.9	5
10	Editorial: natural history of hepatitis delta virusâ€induced liver disease â€less severe today but still needs attention. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 519-520.	3.7	3
11	Epidemiology of Hepatitis B Virus in the Middle East. , 2021, , 91-99.		3
12	Hepatitis Delta Virus Epidemiology in the Industrialized World. <i>AIDS Reviews</i> , 2021, 22, 203-212.	1.0	9
13	The global hepatitis delta virus (HDV) epidemic: what gaps to address in order to mount a public health response?. <i>Archives of Public Health</i> , 2021, 79, 180.	2.4	13
14	A Rapid Point-of-Care Test for the Serodiagnosis of Hepatitis Delta Virus Infection. <i>Viruses</i> , 2021, 13, 2371.	3.3	12
15	Hepatitis Delta Virus Infection: A Large Burden After All?. <i>Journal of Infectious Diseases</i> , 2020, 221, 1573-1575.	4.0	6
16	Tenâ€year followâ€up of a randomized controlled clinical trial in chronic hepatitis delta. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1359-1368.	2.0	47
17	Effect of HBV-HDV co-infection on HBV-HCC co-recurrence in patients undergoing living donor liver transplantation. <i>Hepatology International</i> , 2020, 14, 869-880.	4.2	22
18	Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2020, 73, 1037-1045.	3.7	69

#	ARTICLE	IF	CITATIONS
19	Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2020, 72, 1088-1096.	3.7	75
20	HEV seroprevalence in blood donors in Turkey by two commercial total anti-HEV Ab ELISA kits. <i>Journal of Medical Virology</i> , 2019, 91, 2174-2181.	5.0	6
21	FRI-175-Frequency, severity and impact of Peg-IFNa-associated flares in HDV infection: Results from the HIDIT-II study. <i>Journal of Hepatology</i> , 2019, 70, e466.	3.7	1
22	SAT-171-HEV seroprevalence in blood donors in Turkey: Comparison of two commercial anti-HEV total Ab ELISA kit. <i>Journal of Hepatology</i> , 2019, 70, e704-e705.	3.7	0
23	Acute HBV/HDV Infection. , 2019, , 67-75.		0
24	New treatment options for delta virus: Is a cure in sight?. <i>Journal of Viral Hepatitis</i> , 2019, 26, 618-626.	2.0	33
25	Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 275-286.	9.1	128
26	Regional Epidemiology, Burden, and Management of Hepatitis B Virus in the Middle East. <i>Clinical Liver Disease</i> , 2019, 14, 212-214.	2.1	13
27	Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy. <i>Journal of Hepatology</i> , 2019, 70, 1008-1015.	3.7	90
28	Age and Sex but Not ATP7B Genotype Effectively Influence the Clinical Phenotype of Wilson Disease. <i>Hepatology</i> , 2019, 69, 1464-1476.	7.3	110
29	Evaluation of the results of MOTAKK hepatitis C virus RNA genotyping and hepatitis delta virus external quality assessment programs during 2015-2016. <i>Turkish Journal of Gastroenterology</i> , 2019, 30, 957-963.	1.1	0
30	Interferon Treatment Duration in Patients With Chronic Delta Hepatitis and its Effect on the Natural Course of the Disease. <i>Journal of Infectious Diseases</i> , 2018, 217, 1184-1192.	4.0	78
31	Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. <i>Journal of Hepatology</i> , 2018, 68, 1129-1136.	3.7	88
32	Clinical and virological heterogeneity of hepatitis delta in different regions worldwide: The Hepatitis Delta International Network (<sc>HDIN</sc>). <i>Liver International</i> , 2018, 38, 842-850.	3.9	72
33	Optimizing lonafamib treatment for the management of chronic delta hepatitis: The LOWR HDVâ€ study. <i>Hepatology</i> , 2018, 67, 1224-1236.	7.3	117
34	Management of hepatitis C virus infection in the Asia-Pacific region: an update. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 52-62.	8.1	45
35	The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. <i>Hepatology</i> , 2017, 66, 1444-1453.	7.3	239
36	Discontinuation of Lamivudine Treatment in HBeAg-Negative Chronic Hepatitis B: A Pilot Study with Long-Term follow-up. <i>Antiviral Therapy</i> , 2017, 22, 559-570.	1.0	7

#	ARTICLE	IF	CITATIONS
37	Pharmacokinetics and pharmacodynamics modeling of lonafarnib in patients with chronic hepatitis delta virus infection. <i>Hepatology Communications</i> , 2017, 1, 288-292.	4.3	10
38	Noninvasive fibrosis score for hepatitis delta. <i>Liver International</i> , 2017, 37, 196-204.	3.9	42
39	Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study. <i>Journal of Hepatology</i> , 2017, 66, 11-18.	3.7	52
40	Recent advances in managing hepatitis D. <i>F1000Research</i> , 2017, 6, 1596.	1.6	10
41	Diagnosis, management and treatment of hepatitis B virus infection: Turkey 2017 Clinical Practice Guidelines. <i>Turkish Journal of Gastroenterology</i> , 2017, 28, 73-83.	1.1	10
42	Immunohistochemistry for Viral Hepatitis: Methods and Applications. <i>Biomarkers in Disease</i> , 2017, , 719-733.	0.1	0
43	Future Therapy for Hepatitis B Virus and Hepatitis D Virus. <i>Current Hepatology Reports</i> , 2016, 15, 259-265.	0.9	0
44	PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. <i>Journal of Hepatology</i> , 2016, 64, 800-806.	3.7	358
45	Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2342-2349.e2.	4.4	57
46	Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. <i>Journal of Hepatology</i> , 2015, 62, 363-370.	3.7	138
47	Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 1167-1174.	9.1	216
48	Interleukin-28 gene polymorphisms may contribute to HBsAg persistence and the development of HBeAg-negative chronic hepatitis B. <i>Liver International</i> , 2015, 35, 846-853.	3.9	20
49	Therapy of Delta Hepatitis. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2015, 5, a021543.	6.2	9
50	Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. <i>Hepatology</i> , 2014, 60, 87-97.	7.3	234
51	Manometric assessment of esophageal motor function in patients with primary biliary cirrhosis. <i>European Journal of Internal Medicine</i> , 2014, 25, 230-234.	2.2	5
52	A one step real time PCR method for the quantification of hepatitis delta virus RNA using an external armored RNA standard and intrinsic internal control. <i>Journal of Clinical Virology</i> , 2014, 60, 11-15.	3.1	19
53	Role of immunohistochemistry for hepatitis D and hepatitis B virus in hepatitis delta. <i>Liver International</i> , 2014, 34, 1207-1215.	3.9	7
54	Free circulating nucleic acids in plasma and serum as a novel approach to the use of internal controls in real time PCR based detection. <i>Journal of Virological Methods</i> , 2014, 207, 133-137.	2.1	9

#	ARTICLE	IF	CITATIONS
55	Efficacy of tenofovir in adefovir-experienced patients compared to treatment-naive patients with chronic hepatitis B. <i>Antiviral Therapy</i> , 2014, 19, 543-550.	1.0	11
56	Anti-HDV IgM as a Marker of Disease Activity in Hepatitis Delta. <i>PLoS ONE</i> , 2014, 9, e101002.	2.5	50
57	Hepatitis C virus genotype distribution in Turkey remains unchanged after a decade: Performance of phylogenetic analysis of the NS5B, E1, and 5'UTR regions in genotyping efficiency. <i>Turkish Journal of Gastroenterology</i> , 2014, 25, 405-410.	1.1	16
58	Clonal Analysis of the Quasispecies of Antiviral-Resistant HBV Genomes in Patients with Entecavir Resistance during Rescue Treatment and Successful Treatment of Entecavir Resistance with Tenofovir. <i>Antiviral Therapy</i> , 2013, 18, 77-85.	1.0	12
59	Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients. <i>Hepatology International</i> , 2013, 7, 88-97.	4.2	136
60	Using Chimeric Mice with Humanized Livers to Predict Human Drug Metabolism and a Drug-Drug Interaction. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 344, 388-396.	2.5	48
61	Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: On-treatment kinetics of HBsAg serum levels vary by HBV genotype. <i>Journal of Hepatology</i> , 2013, 59, 1153-1159.	3.7	88
62	Anti-Hdv Immunoglobulin M Testing in Hepatitis Delta Revisited: Correlations with Disease Activity and Response to Pegylated Interferon- $\alpha$ 2A Treatment. <i>Antiviral Therapy</i> , 2012, 17, 305-312.	1.0	25
63	Entecavir Treatment of Chronic Hepatitis D. <i>Clinical Infectious Diseases</i> , 2012, 55, 645-650.	5.8	50
64	Treatment of Chronic Delta Hepatitis. <i>Seminars in Liver Disease</i> , 2012, 32, 237-244.	3.6	56
65	The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country. <i>European Journal of Health Economics</i> , 2012, 13, 663-676.	2.8	24
66	HBsAg-positive hepatitis delta: virological patterns and clinical long-term outcome. <i>Liver International</i> , 2012, 32, 1415-1425.	3.9	52
67	Rapid early HDV RNA decline in the peripheral blood but prolonged intrahepatic hepatitis delta antigen persistence after liver transplantation. <i>Journal of Hepatology</i> , 2012, 56, 115-122.	3.7	74
68	Molecular characterization of a novel entecavir mutation pattern isolated from a multi-drug refractory patient with chronic hepatitis B infection. <i>Journal of Clinical Virology</i> , 2012, 53, 130-134.	3.1	16
69	Potential proteomic biomarkers in assessing liver fibrosis using SELDI-TOF MS. <i>Turkish Journal of Gastroenterology</i> , 2012, 23, 46-53.	1.1	4
70	Pegylated interferon-based treatment in patients with advanced liver disease due to chronic delta hepatitis. <i>Turkish Journal of Gastroenterology</i> , 2012, 23, 560-568.	1.1	22
71	Treatment of chronic hepatitis B with telbivudine: wise hepatologists needed in hepatitis B endemic countries where treatment options are limited. <i>Liver International</i> , 2011, 31, 589-591.	3.9	5
72	Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon $\alpha$ treatment. <i>Liver International</i> , 2011, 31, 1395-1405.	3.9	42

#	ARTICLE	IF	CITATIONS
73	Complete genome sequences and phylogenetic analysis of hepatitis delta viruses isolated from nine Turkish patients. <i>Archives of Virology</i> , 2011, 156, 2215-2220.	2.1	18
74	Peginterferon plus Adefovir versus Either Drug Alone for Hepatitis Delta. <i>New England Journal of Medicine</i> , 2011, 364, 322-331.	27.0	401
75	Serum connective tissue markers as predictors of advanced fibrosis in patients with chronic hepatitis B and D. <i>Turkish Journal of Gastroenterology</i> , 2011, 22, 305-314.	1.1	18
76	The Characteristics and Clinical Outcome of Drug-induced Liver Injury. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, e128-e132.	2.2	35
77	Endoscopic Management of Biliary Parasitic Diseases. <i>Digestive Diseases and Sciences</i> , 2010, 55, 1472-1478.	2.3	34
78	Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis. <i>Liver International</i> , 2010, 30, 430-437.	3.9	96
79	Natural history and treatment of chronic delta hepatitis. <i>Journal of Viral Hepatitis</i> , 2010, 17, 749-756.	2.0	125
80	Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. <i>Hepatology</i> , 2009, 49, 1141-1150.	7.3	418
81	Clinical Characteristics of Inflammatory Bowel Disease in Turkey. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 51-57.	2.2	59
82	Aflatoxin exposure in viral hepatitis patients in Turkey. <i>Turkish Journal of Gastroenterology</i> , 2009, 20, 192-197.	1.1	11
83	Entecavir therapy for lamivudine-refractory chronic hepatitis B: Improved virologic, biochemical, and serology outcomes through 96 weeks. <i>Hepatology</i> , 2008, 48, 99-108.	7.3	173
84	Seropositivity for delta hepatitis in patients with chronic hepatitis B and liver cirrhosis in Turkey: a meta-analysis. <i>Liver International</i> , 2008, 28, 494-498.	3.9	80
85	Treatment of chronic delta hepatitis with lamivudine vs lamivudine+interferon vs interferon. <i>Journal of Viral Hepatitis</i> , 2008, 15, 314-321.	2.0	115
86	Entecavir: a step forward in combating hepatitis B disease. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 3095-3109.	1.8	10
87	PPAR-alpha L162V polymorphism in human hepatocellular carcinoma. <i>Turkish Journal of Gastroenterology</i> , 2008, 19, 245-9.	1.1	5
88	A pilot study of 2 years of interferon treatment in patients with chronic delta hepatitis. <i>Journal of Viral Hepatitis</i> , 2007, 14, 812-816.	2.0	61
89	Hepatitis D. <i>Current Treatment Options in Gastroenterology</i> , 2007, 10, 456-463.	0.8	17
90	Pegylated interferon-alpha plus taurine in treatment of rat liver fibrosis. <i>World Journal of Gastroenterology</i> , 2007, 13, 3237.	3.3	30

#	ARTICLE	IF	CITATIONS
91	A Novel Mutation Pattern Emerging during Lamivudine Treatment Shows Cross-Resistance to Adefovir Dipivoxil Treatment. <i>Antiviral Therapy</i> , 2007, 12, 761-768.	1.0	45
92	Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B. <i>Gastroenterology</i> , 2006, 130, 2039-2049.	1.3	391
93	5-hydroxytryptamine release in the anterior hypothalamic and the hippocampal areas of cholestatic rats. <i>Life Sciences</i> , 2006, 78, 1078-1083.	4.3	5
94	From viral pathobiology to the treatment of hepatitis B virus infection EASL Monothematic Conference (Istanbul, Turkey, October 6-8, 2005). <i>Journal of Hepatology</i> , 2006, 44, 1186-1195.	3.7	8
95	Hepatitis B core antigen expression pattern reflects the response to anti-viral treatment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006, 21, 977-981.	2.8	17
96	Delta hepatitis in Turkey: decreasing but not vanishing and still of concern. <i>Turkish Journal of Gastroenterology</i> , 2006, 17, 74-5.	1.1	4
97	Thrombophilic gene mutations in cirrhotic patients with portal vein thrombosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2005, 17, 339-343.	1.6	62
98	Peroxisome Proliferator-Activated Receptor $\alpha$ 1 L162V Polymorphism in Nonalcoholic Steatohepatitis and Genotype 1 Hepatitis C Virus-Related Liver Steatosis. <i>Journal of Investigative Medicine</i> , 2005, 53, 353-359.	1.6	4
99	Fatigue of cholestasis and the serotonergic neurotransmitter system in the rat. <i>Hepatology</i> , 2005, 41, 731-737.	7.3	24
100	Complete genome sequence and phylogenetic analysis of hepatitis B virus isolated from turkish patients with chronic HBV infection. <i>Journal of Medical Virology</i> , 2005, 76, 476-481.	5.0	61
101	Emergence of a Novel Mutation in the FLLA Region of Hepatitis B Virus during Lamivudine Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 2618-2624.	3.2	11
102	P21 expression and its relation to disease activity and hepatocyte proliferation in chronic hepatitis B virus infection. <i>Turkish Journal of Gastroenterology</i> , 2005, 16, 12-6.	1.1	0
103	Lamivudine Treatment in Hbeag-Negative Chronic Hepatitis B Patients with Low Level Viraemia. <i>Antiviral Therapy</i> , 2005, 10, 319-325.	1.0	9
104	Barrett's esophagus: Prevalence and its relationship with dyspeptic symptoms. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2004, 19, 535-540.	2.8	42
105	Screening for Hemochromatosis in Turkey. <i>Digestive Diseases and Sciences</i> , 2004, 49, 444-449.	2.3	13
106	Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B. <i>New England Journal of Medicine</i> , 2004, 351, 1206-1217.	27.0	1,082
107	A novel pattern (sW195a) in surface gene of HBV DNA due to YSDD (L180M plus M204S) mutation selected during lamivudine therapy and successful treatment with adefovir dipivoxil. <i>Journal of Clinical Virology</i> , 2004, 31, 76-77.	3.1	7
108	Lichen planus and HCV infection in Turkish patients. <i>Turkish Journal of Gastroenterology</i> , 2004, 15, 133-6.	1.1	11

#	ARTICLE	IF	CITATIONS
109	Factor V Leiden, prothrombin G20210A and MTHFR gene mutations in inflammatory bowel disease. Turkish Journal of Gastroenterology, 2004, 15, 250-2.	1.1	15
110	Portal venous system Evaluation with contrast-enhanced 3D MR portography. Clinical Imaging, 2003, 27, 101-105.	1.5	11
111	Blood ammonia determination in cirrhosis: Still confusing after all these years?. Hepatology, 2003, 38, 1307-1310.	7.3	9
112	Hepatic outflow obstruction: enhancement patterns of the liver on MR angiography. European Journal of Radiology, 2003, 48, 203-208.	2.6	13
113	Nuclear Localization of Hepatitis B Core Antigen and Its Relations to Liver Injury, Hepatocyte Proliferation, and Viral Load. Journal of Clinical Gastroenterology, 2003, 36, 269-272.	2.2	25
114	The role of HBeAg seroconversion in acute exacerbation of liver disease with termination of hepatitis B and D virus infection in a chronic hepatitis D patient during $\alpha$ -interferon therapy. European Journal of Gastroenterology and Hepatology, 2003, 15, 819-823.	1.6	7
115	Oral Ganciclovir for Treatment of Lamivudine-Resistant Hepatitis B Virus Infection: A Pilot Study. Clinical Infectious Diseases, 2002, 35, 960-965.	5.8	8
116	Famciclovir treatment of chronic delta hepatitis. Journal of Hepatology, 2002, 37, 266-271.	3.7	103
117	Remission of severe aplastic anemia associated with hepatitis B virus infection after viral clearance: potential role of lamivudine. Digestive Diseases and Sciences, 2002, 47, 1782-1785.	2.3	14
118	Percutaneous transhepatic venoplasty: an alternative treatment for Budd-Chiari syndrome. Turkish Journal of Gastroenterology, 2002, 13, 83-8.	1.1	3
119	Nucleotide divergences in the core promoter and precore region of genotype D hepatitis B virus in patients with persistently elevated or normal ALT levels. Journal of Clinical Virology, 2001, 21, 91-101.	3.1	31
120	Risk factors for hepatocellular carcinoma in Turkey. Digestive Diseases and Sciences, 2001, 46, 1022-1028.	2.3	55
121	The central opioid system in liver disease and its complications. , 2001, 16, 79-83.		10
122	Influence of Viral Load and Alanine Aminotransferase on Viral Genetic Heterogeneity in Patients with Chronic Hepatitis C Virus Infection. Intervirology, 2000, 43, 61-66.	2.8	4
123	Hereditary pancreatitis: Report of a family from Turkey. Pediatrics International, 1998, 40, 612-615.	0.5	0
124	Opioid receptor ligands in human hepatic encephalopathy. Journal of Hepatology, 1998, 29, 796-801.	3.7	35
125	Effect of inhibition of ornithine decarboxylase activity in a model of acute hepatocellular necrosis. European Journal of Gastroenterology and Hepatology, 1998, 10, 503-508.	1.6	1
126	Gut bacteria provide precursors of benzodiazepine receptor ligands in a rat model of hepatic encephalopathy. Brain Research, 1995, 679, 42-48.	2.2	76



#	ARTICLE	IF	CITATIONS
127	Increased serotonergic and noradrenergic activity in hepatic encephalopathy in rats with thioacetamide-induced acute liver failure. <i>Hepatology</i> , 1990, 12, 695-700.	7.3	62
128	Hepatic encephalopathy in thioacetamide-induced acute liver failure in rats: Characterization of an improved model and study of amino acid-ergic neurotransmission. <i>Hepatology</i> , 1989, 9, 594-601.	7.3	161